

<!--StartFragment-->RESULT 4

AAE22843

SEQ ID NO: 9 alignment

ID AAE22843 standard; protein; 802 AA.

XX

AC AAE22843;

XX

DT 21-AUG-2002 (first entry)

XX

DE Human phospholipase A2-like enzyme #5.

XX

KW Human; phospholipase A2-like enzyme; PLA2; asthma; cancer; inflammation;
 KW cardiovascular disorder; central nervous system disease; CNS; diabetes;
 KW obesity; chronic obstructive pulmonary disease; overweight; anorexia;
 KW cachexia; wasting disorder; appetite modulation; eating disorder; stroke;
 KW bulimia; obesity; hypertension; type 2 diabetes; gall bladder disease;
 KW coronary artery disease; hyperlipidaemia; osteoarthritis; sleep apnoea;
 KW respiratory disorder; cancer; polycystic ovarian syndrome; pregnancy;
 KW thrombotic disease; menstrual irregularities; hirsutism; depression;
 KW gout; stress incontinence; gene therapy; cytostatic; cardiant; vulnerary;
 KW nootropic; Anticonvulsant; neuroleptic; tranquiliser; antiinfertility;
 KW analgesic; metabolic; enzyme.

XX

OS Homo sapiens.

XX

PN WO200231162-A2.

XX

PD 18-APR-2002.

XX

PF 09-OCT-2001; 2001WO-EP011642.

XX

PR 10-OCT-2000; 2000US-0238434P.

PR

27-DEC-2000; 2000US-0258051P.

PR

31-AUG-2001; 2001US-0315982P.

XX

PA (FARB) BAYER AG.

XX

PI Zhu Z;

XX

DR WPI; 2002-416866/44.

DR

N-PSDB; AAD36478.

XX

PT New human phospholipase A2-like enzyme polypeptides for treating or
 PT preventing cancer, inflammation, and chronic obstructive pulmonary
 PT disease, diabetes, stroke, dementia and obesity.

XX

PS Claim 25; Fig 9; 164pp; English.

XX

CC The present invention relates to novel human phospholipase A2 (PLA2)-like
 CC enzyme polypeptides and their corresponding proteins. PLA2-like sequences
 CC are useful for treating phospholipase A2-like enzyme dysfunction related
 CC diseases such as asthma, cancer, inflammation, cardiovascular disorder,
 CC central nervous system (CNS) disease, diabetes, obesity and chronic
 CC obstructive pulmonary disease. They are useful for treating overweight,
 CC anorexia, cachexia, wasting disorders, appetite suppression, appetite
 CC enhancement, increases or decreases in satiety, modulation of body weight
 CC and/or other eating disorders such as bulimia, obesity/overweight-
 CC associated comorbidities including hypertension, type 2 diabetes, stroke,
 CC coronary artery disease, hyperlipidaemia, gall bladder disease, gout,
 CC osteoarthritis, sleep apnoea and respiratory problems, endometrial,
 CC breast, prostate, colon cancer, thrombotic disease, polycystic ovarian
 CC syndrome, reduced fertility, complications of pregnancy, menstrual

CC irregularities, hirsutism, stress incontinence and depression. Sequences
 CC of the invention are also used in gene therapy. The present sequence is
 CC human PLA2-like protein
 XX
 SQ Sequence 802 AA;

Query Match 97.8%; Score 4184; DB 5; Length 802;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 802; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	17	EASTCWLTLTVRVLRLRNWADLLSEADPYVILQLSTAPGMFKTKTLTDTSHPVWNEAF	76
Db	1	EASTCWLTLTVRVLRLRNWADLLSEADPYVILQLSTAPGMFKTKTLTDTSHPVWNEAF	60
Qy	77	RFLIQSQVKNVLELSIYDEDSVTEDDIFKVLVDISEVLPGKLLRKTFSQSPQGEELDV	136
Db	61	RFLIQSQVKNVLELSIYDEDSVTEDDIFKVLVDISEVLPGKLLRKTFSQSPQGEELDV	120
Qy	137	EFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELVLKGSYEDT	196
Db	121	EFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELVLKGSYEDT	180
Qy	197	QTSFLGTASAFRPHYMAALETSLGRLSSRSNGWNGDINSAGYLTVPRLPTIGKEVTMD	256
Db	181	QTSFLGTASAFRPHYMAALETSLGRLSSRSNGWNGDINSAGYLTVPRLPTIGKEVTMD	240
Qy	257	VPAPNAPGVRQLKAEQCPPELAVHLGFNLCAEEQAFLSRRKQVVAKALKQALQLDRDLQ	316
Db	241	VPAPNAPGVRQLKAEQCPPELAVHLGFNLCAEEQAFLSRRKQVVAKALKQALQLDRDLQ	300
Qy	317	EDEVVVGIMATGGGARAMTSLYGHLLALQKLGLLDCVITYSGISGSTWTMAHLYGDPWE	376
Db	301	EDEVVVGIMATGGGARAMTSLYGHLLALQKLGLLDCVITYSGISGSTWTMAHLYGDPWE	360
Qy	377	SQRDLGPIRYAREHLAKSKLEVFSPERLASYSRRELELRAEQGHPTTFVDLWALVLESML	436
Db	361	SQRDLGPIRYAREHLAKSKLEVFSPERLASYSRRELELRAEQGHPTTFVDLWALVLESML	420
Qy	437	HGQVMDQKLSQGRAALERGQNPPLPLYLSLNKKNLETLDFKEWVEFSPIYEVGFLKYGAF	496
Db	421	HGQVMDQKLSQGRAALERGQNPPLPLYLSLNKKNLETLDFKEWVEFSPIYEVGFLKYGAF	480
Qy	497	VPPELFGSEFFMGRMLMRIPEPRICFLEAIWSNIFSLNLLDAWYDLSGSGESWKQHIKDK	556
Db	481	VPPELFGSEFFMGRMLMRIPEPRICFLEAIWSNIFSLNLLDAWYDLSGSGESWKQHIKDK	540
Qy	557	TRSLKEPLTTSSTSRLEASWLQPGTALAQAQKGLTGRPLHQSPNPLQGLQLHQDYC	616
Db	541	TRSLKEPLTTSSTSRLEASWLQPGTALAQAQKGLTGRPLHQSPNPLQGLQLHQDYC	600
Qy	617	SHKDFSTWADYQLDSMPSQLTPKEPRLCLVDAAYFINTSSPMFRPGRRLDILSPDYSL	676
Db	601	SHKDFSTWADYQLDSMPSQLTPKEPRLCLVDAAYFINTSSPMFRPGRRLDILSPDYSL	660
Qy	677	SAPFEALQQTLEYCRARGLPFPRVPEPSPQDQHQPRECHLFSDPACPEAPILHHPFLVNAS	736
Db	661	SAPFEALQQTLEYCRARGLPFPRVPEPSPQDQHQPRECHLFSDPACPEAPILHHPFLVNAS	720
Qy	737	FKDHSAPGVQSRPAELQGGQVDLTGATCPYTLNMTYKEEDFERLLRLSDYNVQTSQGA	796
Db	721	FKDHSAPGVQSRPAELQGGQVDLTGATCPYTLNMTYKEEDFERLLRLSDYNVQTSQGA	780

Qy	797	LQALRTALKHRTLEARPPRAQT	818
Db	781	LQALRTALKHRTLEARPPRAQT	802

<!--EndFragment-->